GSK to Cut 1,217 Jobs Across Belgian Sites

GSK announced plans to cut up to 1,217 permanent jobs across its Belgian sites in Wavre, Rixensart, and Gembloux. The layoffs are part of a three-year global restructuring program launched in July to save £1.9 billion by 2029.

CEO Luke Miels initiated the effort to simplify research, manufacturing, and support operations. The company intends to use increased automation and digital tools to accelerate drug development and offset the impact of an impending patent cliff for its HIV drug dolutegravir.

While factory workers are expected to be spared, Belgian labor unions have been formally notified under collective-dismissal procedures. The company stated it will remain the largest biopharmaceutical employer in Belgium and that "Belgium will continue to produce the majority of its vaccines."